ENHANCEMENT OF LUMBAR FUSION W/ RHBMP 2/ COLLAGEN OR LMP

使用 RHBMP 2/胶原蛋白或 LMP 增强腰椎融合

• 批准号: 7562496
• 负责人: SCOTT D. BODEN
• 金额: $ 3.16万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-05-01 至 2008-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7562496
• 关键词: Ceramics; Clinical; Clinical Trials; Collagen; Complication; Computer Retrieval of Information on Scientific Projects Database; Dose; Drug Formulations; Failure; Funding; Genetic Engineering; Grant; Growth Factor; Healed; Human; Implant; Institution; Invasive; Modeling; Monkeys; Oryctolagus cuniculus; Osteogenesis; Paste substance; Primates; Recombinants; Research; Research Personnel; Resistance; Resources; Site; Source; Speed; Spinal Fusion; Testing; Titanium; United States Food and Drug Administration; United States National Institutes of Health; Vertebral column; Work; bone; bone morphogenetic protein 2; bone morphogenetic protein 7; follow-up; healing; nonhuman primate

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Lumbar spinal fusion is commonly performed in humans but the failure of bone union is a frequent complication. Osteoinductive growth factors synthesized by recombinant DNA technology have been shown to induce bone formation in heterotopic sites. Recombinant human BMP-2 (rhBMP-2) has been effective in generating spine fusions in a rabbit model. To determine the dose of the growth factor in humans and to determine the speed of healing, a non-human primate model is used. Higher doses than expected were required to make bone in the primate. The growth factor was delivered inside a hollow titanium threaded fusion cage through a minimally invasive approach. This work resulted in the initiation of a human pilot clinical trial with excellent results at one year follow up. Studies have focused on fine tuning the dose and studying alternative carrier materials including different combinations of ceramic materials for use in the posterolateral spine. We investigated new carriers for BMP-2 and continued studies with LMP-1 and we found that a compression resistant collagen matrix was an effective carrier and this will move on to human trials. Monkeys implanted with rhBMP-2 with a slower release carrier (paste form) and these results demonstrated that the paste was not as effective as previous carriers. In 2006 we tested a proposed clinical formulation of rhBMP-2 and compared it to an earlier formulation that was used in a successful clinical trial. This test demonstrated that the proposed formulation was not as active as the original formulation and resulted in a revised strategy for seeking FDA approval. A second study will directly compare the efficacy of rhBMP-2 to a similar BMP-7 product.

这个子项目是众多研究子项目之一